Reports FY23 revenue $7.144M. “In 2023, we made transformative advancements to build our business, including successfully listing on NASDAQ and have begun 2024 by strengthening our leadership with the appointment of industry veteran, Joshua Boger, Ph.D., as non-executive Chair of the Board,” said John Alam, MD, Chief Executive Officer of CervoMed. “With this momentum, we look forward to building on recent publications that position our lead clinical program, neflamapimod, as a highly differentiated, first-to-market treatment option for patients with DLB. Our RewinD-LB Phase 2b trial is well powered, designed to include patients most likely to benefit from neflamapimod, and is expected to provide a path to market in this high value indication. We remain on track to fully enroll the RewinD-LB trial within the second quarter of this year, followed by availability of topline efficacy results in the fourth quarter of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry
- CervoMed’s Strategic $50 Million Private Placement Deal
- CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
- CervoMed announces private placement financing of up to $149.4M